A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

NCT05551936 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Bendamustine
DRUG: Rituximab
DRUG: Tazemetostat

Sponsor

Vaishalee Kenkre

Collaborators

Epizyme, Inc.
University of Wisconsin, Madison